UBS initiated coverage on Eureka Forbes with a ‘Buy’ call, identifying it as a ‘steady earnings compounder’ with under-appreciated scale advantages in water purifiers and services. The brokerage set a target price of Rs 640, citing market growth driven by health awareness and expanding consumer base.
Syngene zooms 17% despite 19% YoY drop in Q4 profit
Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in
April 30, 2026